Skip to main content

Table 3 Frequencies of response among subjects to the candidate glioma-associated T helper cell epitopes

From: Profound tumor-specific Th2 bias in patients with malignant glioma

  MAGE-A3112-127 MAGE-A3121-136 MAGE-A3143-160 IL-13Rα2341-355 IL-13Rα2351-365
Primary GBM 1   ++ ++++ + +++
Primary GBM 2 ++ ++ +++ ++ ++
Primary GBM 3 ++ ++++ + +++++ ++
Primary GBM 4 + ++ +   +++
Primary GBM 5 +++++ ++++ + ++ +
Primary GBM 6 ++ ++ + ++  
Primary GBM 7 +++ ++++ ++ +++ +++
Primary GBM 8 ++++ ++ +++++ ++++ +++++
Recurrent GBM 1 + ++ + ++ ++
Recurrent GBM 2 +     
Recurrent GBM 3 ++ + +   +
Recurrent GBM 4 ++ + +   
Recurrent GBM 5 + +    ++
Meningioma 1   +    
Meningioma 2   +++    
Meningioma 3      +
Meningioma 4    +   
Meningioma 5 +++    ++ ++
Meningioma 6 + + + + ++++++
Meningioma 7    +   
Healthy Subject 1 +++ +++ +++   +
Healthy Subject 2   + +++ +  
Healthy Subject 3 ++ +++ +   
Healthy Subject 4 ++ + +++++ + +++++
Healthy Subject 5 + + ++ ++++ ++
Healthy Subject 6   + + + ++
  1. Cytokine production was quantified by ELISA, defining a positive T cell response for each patient as the amounts of IFN-γ or IL-5 that were > 50 pg/mL and two standard deviations above the mean cytokine levels secreted after stimulation of cells from that patient with negative control MBP peptide. A total of 6 primary T cell responses were measured for each subject against each peptide. (+) symbols indicate the precise number of positive wells among six for each peptide.